Identification of the interaction between FGF21, BMI, and depression improvement over time suggests that FGF21 is important for people with MDD, who have a lower BMI, but for obese patients other mechanisms may be related to treatment outcomes. Here, FGF21 is linked to depressive symptom measurement.